Clinical Trials
10 trialsNCT04374305 2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT01295944 2025-08-05
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT00883688 2020-08-26
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00463203 2011-06-29
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Rigshospitalet, Denmark
Phase 2 Completed